CD274 and hepatocellular carcinoma: Inhibitors against programmed cell death protein (PD)-1 and its ligand PD-L1 or collectively known as Immune checkpoint blockades (ICBs), are the most recent therapeutic options for many advanced solid malignancies, including HCC (2, 3).